Aline Grosskopf Monich

Aline Grosskopf Monich

Auto-generated profile, based on publicly available information

Aline Grosskopf Monich

Departamento de Clínica Médica, Programa de Pós-Graduação em Medicina Interna e Ciências da Saúde, Universidade Federal do Paraná, Curitiba, Brazil

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in Brazilian Journal of Medical and Biological Research
Verified
Journal Article
Open access
PDF file
AMA.G. Monich
A.G. Monich
RRR.F. Romani
R.F. Romani
JCJ.L.S. Carneiro
J.L.S. Carneiro
Anti-glomerular basement membrane (GBM) disease is a rare and severe vasculitis that affects the glomerular and pulmonary capillaries and has an incidence of less than 2 cases per million individuals per year. Anti-GBM disease is mediated by autoantibodies against the α3 chain of type IV collagen. In the majority of cases, the autoantibodies are of the immunoglobulin G (IgG) class, with rare cases being mediated by immunoglobulin M (IgM) or immunoglobulin A (IgA); there are less than 15 IgA-mediated cases reported in the literature worldwide. The classic form of this disease manifests with rapidly progressive glomerulonephritis (RPGN), with or without pulmonary hemorrhage, and the diagnosis consists of identifying high titers of autoantibodies in the serum and/or deposited in the tissues. IgA antibodies are not identified in routine immunoassay tests, and renal biopsy with immunofluorescence is essential for diagnosis. We present a case of RPGN due to anti-GBM disease with linear IgA deposition, whose diagnosis was made exclusively by renal biopsy and with an unfavorable prognosis.

1 December 2023 in Brazilian Journal of Nephrology
Verified
Journal Article
Open access
PDF file
AMAline Grosskopf Monich
Aline Grosskopf Monich
MCMariana Faucz Munhoz da Cunha
Mariana Faucz Munhoz da Cunha
FBFellype Barreto
Fellype Barreto
We read with great interest the case report “Endovascular treatment of intrarenal aneurysm bleeding and angiomyolipomas in a patient with tuberous sclerosis and polycystic kidney disease” by Leite et al.1 1. Leite T, Pazinato LV, Vidal MJA, Freitas D, Leal Fo JMM. Endovascular treatment of intrarenal aneurysms bleeding and angiomyolipomas in a patient with tuberous sclerosis and polycystic kidney disease. J Bras Nefrol. 2023;45(1):111–5. doi: http://dx.doi.org/10.1590/2175-8239-jbn-2021-0023. PubMed PMID: 34328493. https://doi.org/10.1590/2175-8239-jbn-20... , in which embolization was successfully employed. In cases of bleeding, this preemptive interventional and curative treatment is preferable to partial or total nephrectomy, since it preserves the renal parenchyma and kidney function2 2. Williams JM, Racadio JM, Johnson ND, Donnelly LF, Bissler JJ. Embolization of renal angiomyolipomata in patients with tuberous sclerosis complex. Am J Kidney Dis. 2006;47(1):95–102. doi: http://dx.doi.org/10.1053/j.ajkd.2005.09.028. PubMed PMID: 16377390. https://doi.org/10.1053/j.ajkd.2005.09.0... . Currently, however, the preemptive treatment of choice for tuberous sclerosis-related angiomyolipomas is mTOR inhibitors, not embolization3 3. Bissler JJ, Christopher Kingswood J. Renal manifestation of tuberous sclerosis complex. Am J Med Genet C Semin Med Genet. 2018;178(3):338–47. doi: http://dx.doi.org/10.1002/ajmg.c.31654. PubMed PMID: 30307110. https://doi.org/10.1002/ajmg.c.31654... ,4 4. Li M, Zhou Y, Chen C, Yang T, Zhou S, Chen S, et al. Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis. Orphanet J Rare Dis. 2019;14(1):39. doi: http://dx.doi.org/10.1186/s13023-019-1012-x. PubMed PMID: 30760308. https://doi.org/10.1186/s13023-019-1012-... .

1 September 2024 in Brazilian Journal of Nephrology
Verified
Journal Article
Open access
PDF file
AMAline Grosskopf Monich
Aline Grosskopf Monich
JBJohn J. Bissler
John J. Bissler
FBFellype Barreto
Fellype Barreto
Tuberous sclerosis complex (TSC) is an autosomal dominant disease characterized by the development of hamartomas in the central nervous system, heart, skin, lungs, and kidneys and other manifestations including seizures, cortical tubers, radial migration lines, autism and cognitive disability. The disease is associated with pathogenic variants in the TSC1 or TSC2 genes, resulting in the hyperactivation of the mTOR pathway, a key regulator of cell growth and metabolism. Consequently, the hyperactivation of the mTOR pathway leads to abnormal tissue proliferation and the development of solid tumors. Kidney involvement in TSC is characterized by the development of cystic lesions, renal cell carcinoma and renal angiomyolipomas, which may progress and cause pain, bleeding, and loss of kidney function. Over the past years, there has been a notable shift in the therapeutic approach to TSC, particularly in addressing renal manifestations. mTOR inhibitors have emerged as the primary therapeutic option, whereas surgical interventions like nephrectomy and embolization being reserved primarily for complications unresponsive to clinical treatment, such as severe renal hemorrhage. This review focuses on the main clinical characteristics of TSC, the mechanisms underlying kidney involvement, the recent advances in therapy for kidney lesions, and the future perspectives.

25 January 2024 in BioSCIENCE
Verified
Journal Article
Open access
PDF file
LOLaura Garcia de Andrade Oliveira
Laura Garcia de Andrade Oliveira
AMAline Grosskopf Monich
Aline Grosskopf Monich
JCJoão Luis dos Santos Carneiro
João Luis dos Santos Carneiro
RRRafael Fernandes Romani
Rafael Fernandes Romani

10 September 2025 in Brazilian Journal of Clinical Medicine and Review
Verified
Journal Article
Open access
PDF file
GSGabriel Santos da Silva
Gabriel Santos da Silva
TCThaís Schultz Ciesielski
Thaís Schultz Ciesielski
JCJoão Luiz dos Santos Carneiro
João Luiz dos Santos Carneiro
AMAline Grosskopf Monich
Aline Grosskopf Monich
RRRafael Fernandes Romani
Rafael Fernandes Romani
Injúria renal aguda (IRA) possui alta mortalidade principalmente quando necessita hemodiálise (HD). A infecção de corrente sanguínea relacionada a cateter (ICSRC) é complicação descrita e o principal agente é Staphylococcus aureus. Objetivos deste trabalho são analisar perfil epidemiológico dos pacientes submetidos à HD por IRA e identificar características da ICSRC e desfechos. Estudo observacional, retrospectivo, de pacientes com IRA em HD por cateter duplo lúmen não tunelizado (CDL-NT) durante internamento hospitalar. Levantados dados clínicos, microbiológicos e referentes à HD. Foram incluídos 290 pacientes (65,9% masculino; 62,2±2 anos); 26,9% septuagenários, 49,3% hipertensos e 35,9% diabéticos. IRA em sepse foi a principal etiologia (33,4%); média de sessões de 4,9±3,6/paciente. A incidência de ICSRC foi 14,5%; S. aureus foi o principal agente (30%; 46% MRSA) seguido por A. baumannii (9,6%). Não houve associação entre sexo, idade e local do CDL-NT com ICSRC. Houve maior incidência de ICSRC naqueles que realizaram maior número de sessões de HD (p<0.001). A mortalidade global foi 54,5%. IRA em HD está associada à alta mortalidade e ICSRC é frequente. É notável a prevalência de pacientes idosos e bactérias multirresistentes na amostra estudada.

1 September 2023 in Brazilian Journal of Case Reports
Verified
Journal Article
Open access
PDF file
AMAline Grosskopf Monich
Aline Grosskopf Monich
JCJoão Luis dos Santos Carneiro
João Luis dos Santos Carneiro
FGFelipe Gevert
Felipe Gevert
RRRafael Fernandes Romani
Rafael Fernandes Romani
Hemoperitoneum is common in patients undergoing peritoneal dialysis. Its varied causes include catheter-related complications, obstetric and gynecological etiologies, coagulopathies, and vascular, infectious, and intra-abdominal pathologies. A gynecological etiology, whether pathological or physiological, is the most common cause of hemoperitoneum in adult women undergoing peritoneal dialysis, with more than one-third of cases related to the menstrual cycle. Endometriosis can also cause hemoperitoneum, and the bleeding may originate from endometrial tissue implanted in the peritoneal cavity or that detaches from the intrauterine endometrium during the menstrual period. We report a case of hemoperitoneum in a patient with deep endometriosis and previous hysterectomy who had an excellent response to oral progestin.